ライフサイエンスコーパス: trimethoprim

1 lindamycin, ciprofloxacin, penicillin-G, and trimethoprim).

2 most to the risk followed by lincomycin and trimethoprim.

3 eatment with the nontoxic FDA approved drug, trimethoprim.

4 -150.0 mumolL(-1) for both sulphadiazine and trimethoprim.

5 which code for resistance to sulfonamide and trimethoprim.

6 a metabolite that accumulates on exposure to trimethoprim.

7 RSA was more susceptible to sulfamethoxazole/trimethoprim.

8 , including chloramphenicol, doxycycline and trimethoprim.

9 cular weight and is 82-fold more potent than trimethoprim.

10 darum became sensitive to polymyxin B and/or trimethoprim.

11 trial of azithromycin (20 mg/kg/day) or SXT (trimethoprim 10 mg/kg/day + sulfamethoxazole 50 mg/kg/da

12 79%; amoxicillin, 78%; cephalosporins, 31%; trimethoprim, 20%; piperacillin-tazobactam, 11%; chloram

13 diate (33.8-43.6%), tetracycline (30.4%) and trimethoprim (22.6%) intermediate to high heat stability

14 al degradation products of the antimicrobial trimethoprim (290 Da) is described.

15 (6.02; 95%CI: 3.31-8.73), sulfamethoxazole/ trimethoprim (4.49; 95%CI: 2.42-6.56), cefpodoxime (1.91

16 chloramphenicol, 49% (95% CI, 0.20 to 0.83); trimethoprim, 45% (95% CI, 0.22 to 0.74); piperacillin-t

17 robial catheter lock solution that contained trimethoprim 5 mg/mL, ethanol 25%, and Ca-EDTA 3% (inves

18 .6%; gentamicin, 80.6%; and sulfamethoxazole/trimethoprim, 59.4%.

19 n, 100%; gentamicin, 88.0%; sulfamethoxazole/trimethoprim, 77.5%; levofloxacin, 58.5%; oxacillin, 54.

20 ngle-center study comparing sulfamethoxazole-trimethoprim 800/160 mg (SMZ/TMP) daily for 30 days foll

21 ibition and MIC values near or below that of trimethoprim against wild-type S. aureus.

22 lesser extent, azithromycin, cefotaxime, and trimethoprim all pose a significant risk for selection o

23 Therefore, modification of trimethoprim, an antibacterial drug with no tumor growth

24 d by mothers in once-daily regimens of 20 mg trimethoprim and 100 mg sulfamethoxazole orally (age <6

25 age <6 months or bodyweight <5 kg), or 40 mg trimethoprim and 200 mg sulfamethoxazole orally (age >6

26 Analogue 17 was 50-fold more potent than trimethoprim and about twice as selective against T. gon

27 atter accumulation in these soils can retard trimethoprim and carbamazepine dissipation.

28 Trimethoprim and sulfamethizole are both folate biosynth

29 e focus on combinations with the antibiotics trimethoprim and sulfamethizole, which had been standard

30 LEW1.WR1 rats with KRV and a combination of trimethoprim and sulfamethoxazole (Sulfatrim) beginning

31 Biotransformation rates increased for trimethoprim and sulfamethoxazole in the dark, when micr

32 sting that long-term treatment with combined trimethoprim and sulfamethoxazole prevented recurrent di

33 ed in the pilot-scale system (t1/2 < 0.5 d), trimethoprim and sulfamethoxazole were transformed more

34 sfully treated for PcP with a combination of trimethoprim and sulfamethoxazole.

35 infections is co-trimoxazole, a cocktail of trimethoprim and sulfamethoxazole.

36 broadly used combinatory antibiotic therapy, trimethoprim and sulfonamides.

37 anced sequestration of cationic or uncharged trimethoprim and uncharged carbamazepine, but did not af

38 d several that synergize with the antibiotic trimethoprim and/or sulfamethizole.

39 fadiazine, sulfamethazine, sulfamethoxazole, trimethoprim) and incubated with flood water of differen

40 Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir were administered prophylact

41 polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin (PANTA) was added, the tube

42 classes, namely ciprofloxacin, tetracycline, trimethoprim, and erythromycin, demonstrated pronounced

43 chloramphenicols, tetracycline, macrolides, trimethoprim, and sulfonamides) was evaluated in surface

44 nitrofurantoin, quinolone, sulphonamide and trimethoprim, and tetracycline) and the occurrence of RA

45 on was treated with amikacin and polymyxin B-trimethoprim, and the ulcer resolved over 3 weeks.

46 rved by LDPI-MS in response to rifampicin or trimethoprim antibiotic treatment.

47 Usage of sulphonamide and trimethoprim antibiotics, is associated with a 70% incre

48 osis was made, and Bactrim (sulfamethoxazole-trimethoprim; AR Scientific, Philadelphia, Pa) and a reg

49 The continuously increasing use of trimethoprim as a common antibiotic for medical use and

50 sensitive to the clinically used antifolate, trimethoprim, because of a lack of potency against the d

51 ultaneous determination of sulphadiazine and trimethoprim by spectrophotometry in some bovine milk an

52 Here, we examine the effect the covalent trimethoprim chemical tag (A-TMP-tag) has on the SM imag

53 arately with NADPH, dihydrofolate and NADPH, trimethoprim), compounds 2 and 3 were optimized for inhi

54 l cells in the guts increased with increased trimethoprim concentration, ingestion and incorporation

55 e genetic elements, such as sulfamethoxazole-trimethoprim constins and class I integrons, and common

56 Here we demonstrate that trimethoprim derivatives can be used to selectively tag

57 encoded tetracycline [tetA(A) and tetA(G)], trimethoprim [dfrA1, dfrA5, dfrA7, dfrA12, and dfrA15],

58 Trimethoprim dissipation was even slower in soils irriga

59 s of the cytotoxic polyketide malleilactone; trimethoprim does so by increasing expression of the mal

60 followed by sulfadiazine (DT(50) = 53 days), trimethoprim (DT(50) = 3 days) and sulfamethoxazole (DT(

61 Trimethoprim elicits an upregulation of the mal gene clu

62 strategies for albendazole, chloramphenicol, trimethoprim, enrofloxacin, oxitetracycline and nicarbaz

63 In patients on chronic HD, a trimethoprim, ethanol, and Ca-EDTA lock solution signifi

64 We report that B. thailandensis grown on trimethoprim exhibited increased virulence against Caeno

65 Specifically, we designed an acrylamide-trimethoprim-fluorophore (A-TMP-fluorophore v2.0) electr

66 In daphnids exposed to 0.25 mg L(-1) trimethoprim for 24 h, the microbiota was strongly affec

67 ed in the animals exposed to 0.25-2 mg L(-1) trimethoprim for 48 h and then fed 14C-labeled algae.

68 c activities of their protein targets (i.e., trimethoprim for dihydrofolate reductase), thus disrupti

69 in, tetracycline, ciprofloxacin, vancomycin, trimethoprim, gentamicin, fusidic acid, rifampin, and mu

70 ique show that among all tested antibiotics, trimethoprim has the lowest antimicrobial effect on B. b

71 than the currently employed front-line drug trimethoprim (IC(50) = 46 microM).

72 ion used for extraction of sulphadiazine and trimethoprim in bovine milk.

73 nce B (EmrB) family is a primary exporter of trimethoprim in Burkholderia thailandensis, as evidenced

74 crolides, 7 quinolones, 6 tetracyclines, and trimethoprim in chlorine-disinfected drinking water usin

75 sulfonamides, which is generally mixed with trimethoprim in pharmaceutical products, has been chosen

76 of the involvement of DNA repair enzymes in trimethoprim-induced cytotoxicity clearly indicates that

77 The antibiotic trimethoprim is frequently used to manage Burkholderia i

78 ers and oral co-trimoxazole suspension (8 mg trimethoprim/kg and 40 mg sulfamethoxazole/kg/day) for 5

79 in (HA) tag, GFP-DDDHA, which was induced by trimethoprim-lactate (TMP-lactate), which results in the

80 xposure to the antibiotics ciprofloxacin and trimethoprim leads to the formation of double strand bre

81 tase inhibitors characterized by an extended trimethoprim-like scaffold.

82 s wide distribution of ARGs for sulfonamide, trimethoprim, macroline, beta-lactams and chloramphenico

83 Trimethoprim, mecoprop, nonprescription pharmaceuticals,

84 Trimethoprim mediated concentration-dependent diminution

85 d purine homeostasis plays a primary role in trimethoprim-mediated induction of malR and in turn malA

86 35), Ofloxacin (n=3117) and Sulfamethoxazole-Trimethoprim (n=3544).

87 We examined effects of the antibiotic trimethoprim on microbiota of Daphnia magna and concomit

88 egulation of malA and malR, with addition of trimethoprim or allopurinol also resulting in an equival

89 [(18)F]fluoropropyl-trimethoprim, or [(18)F]FPTMP, shows a greater than 100-

90 ond mutant that was resistant to lincomycin, trimethoprim, or rifampin.

91 Escherichia coli to grow in the presence of trimethoprim plus added sorbitol parallels the catalytic

92 were enrolled in the study; 29 patients used trimethoprim/polymyxin B drops, and 11 patients used flu

93 Removal of acetaminophen, ciprofloxacin, trimethoprim, propranolol, and carbamazepine (>80%) was

94 Transformation of trimethoprim, propranolol, and carbamazepine was attribu

95 terize a multi-peaked adaptive landscape for trimethoprim resistance by constructing all combinatoria

96 In contrast, trimethoprim resistance evolved in a stepwise manner, th

97 l experiments revealed that the mechanism of trimethoprim resistance in B. bacteriovorus depends on t

98 There was no significant difference in trimethoprim resistance rates between study and control

99 se without Mfd, at least during evolution of trimethoprim resistance.

100 inations inhibit the growth and virulence of trimethoprim-resistant clinical Escherichia coli and Kle

101 propargyl-linked antifolates (PLAs) against trimethoprim-resistant dihydrofolate reductase (DHFR) fr

102 R inhibitors that are active against several trimethoprim-resistant enzymes.

103 S. aureus of 0.0125 mug/mL and a MIC versus trimethoprim-resistant S. aureus of 0.25 mug/mL.

104 cedure was applied to 22 feed samples, where trimethoprim, robenidine, or alpha- and beta-nandrolone

105 ria thailandensis, as evidenced by increased trimethoprim sensitivity after inactivation of emrB, the

106 One of these antibiotics, trimethoprim, served as a global activator of secondary

107 Trimethoprim-SMX with rifampin is an efficient treatment

108 testing trimethoprim-sulfamethoxazole and/or trimethoprim-sulfadiazine with S. equi This study indica

109 famethoxazole as an acceptable surrogate for trimethoprim-sulfadiazine with S. equi.

110 ntimicrobial susceptibility test results for trimethoprim-sulfadiazine with Streptococcus equi subspe

111 dard oral regimen based on trial evidence is trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline

112 Trimethoprim-sulfamethoxazole (160/800 mg twice daily fo

113 and, to a lesser extent, to kanamycin (19%), trimethoprim-sulfamethoxazole (17%), and gentamicin (11%

114 ) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (5

115 ), ethambutol (92%), and sulfamethoxazole or trimethoprim-sulfamethoxazole (70%).

116 ythromycin (73.9%), clindamycin (65.5%), and trimethoprim-sulfamethoxazole (80%); however, categorica

117 were successfully treated in all cases using trimethoprim-sulfamethoxazole (800 mg/160 mg) twice dail

118 . emergency departments to determine whether trimethoprim-sulfamethoxazole (at doses of 320 mg and 16

119 to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]

120 esistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant [MDR]

121 esistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant S. Ty

122 24), abacavir (n = 11), nevirapine (n = 14), trimethoprim-sulfamethoxazole (n = 11), dapsone (n = 4),

123 P = 0.016) and less frequently resistant to trimethoprim-sulfamethoxazole (OR = 0.38; 95% CI = 0.18

124 ce to amoxicillin-clavulanic acid (P = .03), trimethoprim-sulfamethoxazole (P = .01), and ciprofloxac

125 Azithromycin and trimethoprim-sulfamethoxazole (SXT) are widely used to t

126 Overall ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (SXT), and cefazolin (CFZ)

127 us urinae has been described as resistant to trimethoprim-sulfamethoxazole (SXT), but the test medium

128 drug (27%), followed by phosphomycin (23%), trimethoprim-sulfamethoxazole (TMP-SMX) (9%), and cefuro

129 Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinol

130 Daily trimethoprim-sulfamethoxazole (TMP-SMX) and insecticide-

131 Long-term antibiotic therapy included oral trimethoprim-sulfamethoxazole (TMP-SMX) and rifampin, TM

132 Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly pre

133 a 1:1 ratio to receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days.

134 drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 wee

135 drugs like HIV protease inhibitors (PIs) and trimethoprim-sulfamethoxazole (TMP-SMX) have known activ

136 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used i

137 44) or HIV exposed (n = 175) and prescribed trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

138 up to 42 days, primarily in those receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

139 lin, 649 (58%) to streptomycin, 402 (36%) to trimethoprim-sulfamethoxazole (TMP-SMX), 355 (32%) to su

140 in, 19 isolates (43%) were nonsusceptible to trimethoprim-sulfamethoxazole (TMP-SMX), and all isolate

141 re randomly assigned to receive clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or placebo for

142 Additionally, trimethoprim-sulfamethoxazole (TMP-SMX), used for opport

143 of urinary tract infections (UTI) caused by trimethoprim-sulfamethoxazole (TMP-SMX)-resistant Escher

144 Trimethoprim-sulfamethoxazole (TMP-SMZ) and the fluoroqu

145 Trimethoprim-sulfamethoxazole (TMP-SMZ) is an alternativ

146 these organisms is typically susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ), and this theref

147 iving antiretroviral therapy (ART) and daily trimethoprim-sulfamethoxazole (TMP/SXT).

148 onthly sulfadoxine-pyrimethamine (SP), daily trimethoprim-sulfamethoxazole (TS), or monthly dihydroar

149 d accounted for >/=40% (beta-lactams), >50% (trimethoprim-sulfamethoxazole , multidrug), or >70% (cip

150 oramphenicol, doxycycline, sulfadiazine, and trimethoprim-sulfamethoxazole [TMP-SMX]) and abstracted

151 ence implementing a protocolized approach to trimethoprim-sulfamethoxazole adverse drug reaction asse

152 Forty-two patients (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions doc

153 zole, as compared with standard prophylaxis (trimethoprim-sulfamethoxazole alone).

154 showed that all strains were susceptible to trimethoprim-sulfamethoxazole and ciprofloxacin.

155 With trimethoprim-sulfamethoxazole and fluoroquinolones, the

156 was 0 of 46 (0%) and 6 of 47 (12.80%) in the trimethoprim-sulfamethoxazole and placebo groups, respec

157 ted in vivo by treatment with the antibiotic trimethoprim-sulfamethoxazole and possibly by coinfectio

158 boratory interpretation of in vitro MICs for trimethoprim-sulfamethoxazole and sulfamethoxazole and t

159 Additional prophylaxis included trimethoprim-sulfamethoxazole and valganciclovir.

160 th resistance to ampicillin, gentamicin, and trimethoprim-sulfamethoxazole and with susceptibility to

161 solates were found to have resistant MICs of trimethoprim-sulfamethoxazole and/or sulfamethoxazole.

162 tudy support a single breakpoint for testing trimethoprim-sulfamethoxazole and/or trimethoprim-sulfad

163 nded-spectrum penicillins, tetracycline, and trimethoprim-sulfamethoxazole are good treatment options

164 lfadiazine with S. equi This study indicates trimethoprim-sulfamethoxazole as an acceptable surrogate

165 venous vancomycin followed by 1 week of oral trimethoprim-sulfamethoxazole combination therapy.

166 cated cellulitis, the use of cephalexin plus trimethoprim-sulfamethoxazole compared to cephalexin alo

167 81.0%) to chloramphenicol, and 93 (92.1%) to trimethoprim-sulfamethoxazole compared with 22 (62.9%),

168 Current antiretroviral therapy or use of trimethoprim-sulfamethoxazole did not impact the risk of

169 In 36%, trimethoprim-sulfamethoxazole dosage was elevated by cur

170 24-month visit for 428 children (214 in the trimethoprim-sulfamethoxazole group and 214 in the place

171 loped in 2 of 524 participants (0.4%) in the trimethoprim-sulfamethoxazole group and in 2 of 533 part

172 Weight gain in the trimethoprim-sulfamethoxazole group and the placebo grou

173 ed in 507 of 630 participants (80.5%) in the trimethoprim-sulfamethoxazole group versus 454 of 617 pa

174 ed in 487 of 524 participants (92.9%) in the trimethoprim-sulfamethoxazole group versus 457 of 533 pa

175 ) of 218 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 165 (85.5%) of 19

176 ) of 248 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 171 (69.0%) of 24

177 had developed in 1 participant (0.2%) in the trimethoprim-sulfamethoxazole group.

178 to sulfisoxazole in 21.7% of strains and to trimethoprim-sulfamethoxazole in 21.0% resulted from pol

179 s of isoniazid-pyridoxine (coformulated with trimethoprim-sulfamethoxazole in a single fixed-dose com

180 Resistance to trimethoprim-sulfamethoxazole in Iran is low and this dr

181 While trimethoprim-sulfamethoxazole is considered first-line t

182 Trimethoprim-sulfamethoxazole is the preferred drug regi

183 Trimethoprim-sulfamethoxazole or placebo taken orally, o

184 Additionally, each was randomized to trimethoprim-sulfamethoxazole or placebo.

185 l prophylaxis, which consisted of continuous trimethoprim-sulfamethoxazole plus at least 12 weeks of

186 nomic outcomes associated with no treatment, trimethoprim-sulfamethoxazole prophylaxis alone, antiret

187 ting and clinical criteria, as compared with trimethoprim-sulfamethoxazole prophylaxis alone.

188 A strategy of trimethoprim-sulfamethoxazole prophylaxis and antiretrov

189 Women received daily trimethoprim-sulfamethoxazole prophylaxis and insecticid

190 uster, which was controlled after systematic trimethoprim-sulfamethoxazole prophylaxis in exposed pat

191 ract infection, we evaluated the efficacy of trimethoprim-sulfamethoxazole prophylaxis in preventing

192 , and no further cases were identified after trimethoprim-sulfamethoxazole prophylaxis was introduced

193 lysis of data from a large clinical trial of trimethoprim-sulfamethoxazole prophylaxis, there was no

194 re as cost-effective as those that also used trimethoprim-sulfamethoxazole prophylaxis.

195 Significantly more patients underwent trimethoprim-sulfamethoxazole rechallenge after protocol

196 The introduction of a standard approach to trimethoprim-sulfamethoxazole rechallenge in the context

197 foreign travel significantly predicted both trimethoprim-sulfamethoxazole resistance (prevalence rat

198 emergent pulsotype 2123 was associated with trimethoprim-sulfamethoxazole resistance and K1 (versus

199 Trimethoprim-sulfamethoxazole retains clinical efficacy,

200 cellulitis without abscess, the addition of trimethoprim-sulfamethoxazole to cephalexin did not impr

201 In settings in which MRSA was prevalent, trimethoprim-sulfamethoxazole treatment resulted in a hi

202 roportion of isolates that were resistant to trimethoprim-sulfamethoxazole was 63% in the prophylaxis

203 Trimethoprim-sulfamethoxazole was associated with slight

204 ntly prescribed antibiotic at the beginning, trimethoprim-sulfamethoxazole was most frequently prescr

205 Trimethoprim-sulfamethoxazole was superior to placebo wi

206 ntly prescribed antibiotic at the beginning, trimethoprim-sulfamethoxazole was the most frequently pr

207 Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood

208 To determine whether cephalexin plus trimethoprim-sulfamethoxazole yields a higher clinical c

209 Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered

210 have suggested benefit with co-trimoxazole (trimethoprim-sulfamethoxazole).

211 Cephalexin, 500 mg 4 times daily, plus trimethoprim-sulfamethoxazole, 320 mg/1600 mg twice dail

212 onsusceptible to penicillin, macrolides, and trimethoprim-sulfamethoxazole, 8 had other resistance pa

213 n, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%.

214 s is complicated by increasing resistance to trimethoprim-sulfamethoxazole, amoxicillin/clavulanic ac

215 occus spp. had high MICs of >4/76 mug/ml for trimethoprim-sulfamethoxazole, an antibiotic commonly us

216 luoroquinolones, 100 percent to rifampin and trimethoprim-sulfamethoxazole, and 92 percent to tetracy

217 al variation in resistance to ciprofloxacin, trimethoprim-sulfamethoxazole, and ampicillin in communi

218 Reduced susceptibility to tetracycline, trimethoprim-sulfamethoxazole, and chloramphenicol was o

219 d oral antimicrobials: namely, azithromycin, trimethoprim-sulfamethoxazole, and ciprofloxacin.

220 pregnant women who received bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretro

221 ant women with HIV receiving bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretro

222 to carbapenems but susceptible to aztreonam, trimethoprim-sulfamethoxazole, and fluoroquinolones.

223 -MRSA is usually susceptible to clindamycin, trimethoprim-sulfamethoxazole, and rifampin, but inducib

224 ropenem, penicillin, rifampin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin.

225 penem, penicillin (PEN), tetracycline (TET), trimethoprim-sulfamethoxazole, and vancomycin.

226 n, erythromycin, tetracycline, streptomycin, trimethoprim-sulfamethoxazole, chloramphenicol, and gent

227 d for the following agents: chloramphenicol, trimethoprim-sulfamethoxazole, ciprofloxacin, and rifamp

228 st gram-negative bacilli-but mostly not EPE (trimethoprim-sulfamethoxazole, fluoroquinolones, oral ce

229 mportant difference favoring cephalexin plus trimethoprim-sulfamethoxazole, further research may be n

230 lumefantrine exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is

231 Immediate antimicrobial therapy with trimethoprim-sulfamethoxazole, nitrofurantoin, or fosfom

232 cases were treated with other beta-lactams, trimethoprim-sulfamethoxazole, or vancomycin.

233 ted CAS, the most common antimicrobials were trimethoprim-sulfamethoxazole, penicillin, and amoxicill

234 However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent par

235 were sensitive to minocycline, doxycycline, trimethoprim-sulfamethoxazole, vancomycin, teicoplanin,

236 and N. otitidiscaviarum were susceptible to trimethoprim-sulfamethoxazole, while 8% of N. farcinica

237 Prophylaxis most frequently involves trimethoprim-sulfamethoxazole, with second-line therapie

238 cible clindamycin resistance (ICR) (n = 30), trimethoprim-sulfamethoxazole-resistant MRSA (n = 10), v

239 ycycline, 29.7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole.

240 acin, imipenem, linezolid, moxifloxacin, and trimethoprim-sulfamethoxazole.

241 ciprofloxacin, clindamycin, gentamicin, and trimethoprim-sulfamethoxazole.

242 oxacin, clindamycin, gentamicin sulfate, and trimethoprim-sulfamethoxazole.

243 at Y. pestis, except for chloramphenicol and trimethoprim-sulfamethoxazole.

244 ompared by testing 567 staphylococci against trimethoprim-sulfamethoxazole.

245 e mice also received antibiotic therapy with trimethoprim-sulfamethoxazole.

246 0-day outpatient course of ciprofloxacin and trimethoprim-sulfamethoxazole.

247 lls/microL, despite anti-Pc prophylaxis with trimethoprim-sulfamethoxazole.

248 penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole.

249 All infants also received high-dose trimethoprim-sulfamethoxazole.

250 osporins, fluoroquinolones, penicillins, and trimethoprim-sulfamethoxazole.

251 acin, gentamicin, rifampin, minocycline, and trimethoprim-sulfamethoxazole.

252 ftriaxone, ciprofloxacin, gentamicin, and/or trimethoprim-sulfamethoxazole.

253 luded serotypes 19A and 23F was resistant to trimethoprim-sulfamethoxazole.

254 utrients, and postdischarge prophylaxis with trimethoprim-sulfamethoxazole.

255 utrients, and postdischarge prophylaxis with trimethoprim-sulfamethoxazole.

256 cies are interpreted based on human data for trimethoprim-sulfamethoxazole.

257 esistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole; 4 were also resistant to

258 While antifolates such as Bactrim (trimethoprim-sulfamethoxazole; TMP-SMX) continue to play

259 and levofloxacin among S. pneumoniae and for trimethoprim/sulfamethoxazole and azithromycin among H.

260 Trimethoprim/sulfamethoxazole prophylaxis was associated

261 maining patients were randomized to Group 1 (trimethoprim/sulfamethoxazole tablet every 2 days) or Gr

262 Trimethoprim/sulfamethoxazole therapy resulted in a 100%

263 effect of aminopenicillin, fluoroquinolone, trimethoprim/sulfamethoxazole, and tetracycline usage on

264 f isolates were resistant to clindamycin and trimethoprim/sulfamethoxazole, respectively.

265 olid, minocyline, tigecycline, rifampin, and trimethoprim/sulfamethoxazole.

266 any urinary antibiotic (eg, nitrofurantoin, trimethoprim/sulfonamides, ciprofloxacin) in the 30 days

267 her rates of resistance to gentamicin (43%), trimethoprim-sulphamethoxazole (60%), and ciprofloxacin

268 tics, with the exception of sulfamethoxazole-trimethoprim (SXT).

269 Several antifolates, including trimethoprim (TMP) and a series of propargyl-linked anal

270 using cyclic voltammetry in the presence of Trimethoprim (TMP) as template molecules.

271 ity (DeltaG(0)(coop) = -2.9 kcal mol(-1)) of trimethoprim (TMP) binding to a bacterial dihydrofolate

272 distribution of sulfamonomethoxine (SMM) and trimethoprim (TMP) in egg yolk and white was measured du

273 of E. coli dihydrofolate reductase (DHFR) by trimethoprim (TMP) prevents growth, but this can be reli

274 ictive biophysics-based fitness landscape of trimethoprim (TMP) resistance for Escherichia coli dihyd

275 ue in spDHFR is the critical element for the trimethoprim (TMP) resistance.

276 Trimethoprim (TMP) that specifically binds to eDHFR was

277 On the basis of the high affinity binding of trimethoprim (TMP) to Escherichia coli dihydrofolate red

278 m pjDHFR and pcDHFR with methotrexate (MTX), trimethoprim (TMP), and its potent analogue, PY957.

279 ticals (carbamazepine (CBZ), naproxen (NAP), trimethoprim (TMP), and sulfonamide antibiotics (SAs)) i

280 FR and its binary and ternary complexes with trimethoprim (TMP), folinic acid and coenzymes (NADPH/NA

281 gh antiparasitic vs mammalian selectivity of trimethoprim (TMP), the heretofore undescribed 2,4-diami

282 thazine, SMZ; and sulfadimethoxine, SDM) and trimethoprim (TMP).

283 ose activity is controlled by the antibiotic trimethoprim (TMP).

284 ins is regulated by the simple folate analog trimethoprim (TMP).

285 tagonists, including the antibacterial agent trimethoprim (TMP).

286 ction based on the small-molecule antibiotic trimethoprim (TMP).

287 sis for how baDHFR has natural resistance to trimethoprim (TMP; 2).

288 8 and Phe34, rationalizing weaker binding of trimethoprim to Leu100 DHFR.

289 e characterized molecular mechanisms whereby trimethoprim treatment results in cell death, using Esch

290 Cloned MMTV proviruses carrying a trimethoprim (trim) cassette in the envelope gene were d

291 of mixtures of three major use antibiotics (trimethoprim, tylosin, and lincomycin) to algal and cyan

292 d low amounts of thymidine were treated with trimethoprim under aerobic and anaerobic conditions.

293 ion of thymidine and increases resistance to trimethoprim under both aerobic and anaerobic conditions

294 tetracycline, streptomycin, and sulfonamide/trimethoprim was assigned to a single mosaic region on a

295 Use of sulphonamide and trimethoprim was associated with an increased risk of RA

296 similar increase in malR/malA expression as trimethoprim, we suggest that impaired purine homeostasi

297 its of detection (LOD) for sulphadiazine and trimethoprim were 0.86 and 0.92 mumolL(-1), respectively

298 -fold (C. hominis and T. gondii) relative to trimethoprim were generated by synthesizing just 14 new

299 vivo selection using the antibacterial drug, trimethoprim, where the water content of the media is de

300 t-scale system for atenolol, metoprolol, and trimethoprim, while sulfamethoxazole and propranolol wer